Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE 158 Study.
PURPOSE KEYNOTE 158 ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from patients with previously treated advanced cervical cancer. PATIENTS AND METHODS Patients received pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision. Tumor imaging was performed every 9 weeks for the first 12 months and every 12 weeks thereafter. The primary end point was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors (version 1.1) by independent central radiologic review. Safety was a secondary end point. RESULTS Ninety eight patients were treated. Median age was 46.0 years (range, 24 to 75 years) and 65.3% of patients had Eastern Cooperative Oncology Group performance status of 1. Eighty two patients (83.7% had programmed death ligand 1 (PD L1) positive tumors (combined positive score 1) 77 having previously received one or more lines of chemotherapy for recurrent or metastatic disease. Median follow up was 10.2 months (range, 0.6 to 22.7 months) ORR was 12.2% (95% CI, 6.5% to 20.4% with three complete and nine partial responses. All 12 responses were in patients with PD L1 positive tumors, for an ORR of 14.6% (95% CI, 7.8% to 24.2% 14.3% (95% CI, 7.4% to 24.1% of these responses were in those who had received one or more lines of chemotherapy for recurrent or metastatic disease. Median duration of response was not reached (range, 3.7 to 18.6 months) Treatment related adverse events occurred in 65.3% of patients, and the most common were hypothyroidism (10.2% decreased appetite (9.2% and fatigue (9.2% Treatment related grade 3 to 4 adverse events occurred in 12.2% of patients. CONCLUSION Pembrolizumab monotherapy demonstrated durable antitumor activity and manageable safety in patients with advanced cervical cancer. On the basis of these results, the US Food and Drug Administration granted accelerated approval of pembrolizumab for patients with advanced PD L1 positive cervical cancer who experienced progression during or after chemotherapy.
Journal of clinical oncology official journal of the American Society of Clinical Oncology